Leukemia cells may evade therapy by switching survival signaling pathways
A study combining computer modeling with patient-derived cells found that chronic lymphocytic leukemia cells can alternate between survival signals, potentially explaining variable treatment responses. The work focused on B-cell receptor signaling and resistance to Bruton's tyrosine kinase inhibitors. Researchers say the findings could support more personalized treatment approaches.
CLL is the most common leukemia in adults and currently cannot be cured, so patients often need long-term management. BTK inhibitors work by interfering with BCR signaling, a communication route that helps malignant cells remain in protective lymph node environments; treatment pushes them into circulation where they are more vulnerable.
In relapsed cases, 20–30% lack detectable mutations explaining resistance. This study paired a detailed computational model of BCR signaling with patient-derived CLL cells, a first according to the material. It suggests cells can rely on TLR9 signaling when BCR is blocked, offering a possible resistance mechanism.
For patients with CLL and their clinicians, this work could eventually inform treatment selection by flagging likely resistance patterns before they become clinically apparent. It may help explain why some BTK inhibitor regimens succeed while others fail, potentially guiding earlier combination strategies and reducing exposure to ineffective drugs. Because the findings come from modeling plus patient-derived cells, their practical value will depend on further validation; any societal benefit would likely be gradual and concentrated among people receiving targeted leukemia therapy.